When it comes to biotech in 2021, the author of today’s article expects the sector to remain very attractive, noting that “Valuations are quite reasonable and earnings have steadily increased. […]
read moreWhen it comes to biotech in 2021, the author of today’s article expects the sector to remain very attractive, noting that “Valuations are quite reasonable and earnings have steadily increased. […]
read more